In a recent interview, Esperion President and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases.
Cytokinetics drug Myqorzo won FDA approval for treating obstructive hypertrophic cardiomyopathy, or oHCM. Compared to Bristol Myers Squibb’s projected blockbuster drug Camzyos, the Cytokinetics daily pill has less restrictive safety and monitoring requirements, giving it a competitive advantage, according to analysts.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
The FDA approved Bayer’s Kerendia for reducing the risk of heart failure in patients with mildly reduced ejection fraction, a measure of how much blood the organ can pump. The daily pill was first approved in 2021 for patients with chronic kidney disease associated with type 2 diabetes.
With better access to tools like CCTA and diagnostic tools that leverage CCTA, clinicians can better support their patients in managing overall cardiovascular health, patients will benefit from less invasive care and enhanced quality of life, and health systems could ultimately see reduced costs and streamlined workflows.
Providence Health Plan and the American Heart Association will create blood pressure programs in 20 community organizations and clinics over three years.
Peripheral IV insertion and blood collection are two of the most prevalent inpatient procedures in U.S. hospitals. Here's how clinicians can advocate for a better, more compassionate care experience without extra “sticks.”
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
As with so many other conditions, in vascular health, patients often need to be seen within a few days or weeks, but current referral systems drag on for many weeks and months.
Five ways stakeholders can promote screening and treatment for elevated Lp(a) in the future to improve overall cardiac disease mortality
Merck drug Winrevair is the first in a new class of pulmonary arterial hypertension therapies that address a key signaling pathway behind the disease. The drug comes from Merck’s $11.5 billion acquisition of Acceleron Pharma.
Cytokinetics drug aficamten met the main goal of a pivotal test in obstructive hypertrophic cardiomyopathy. If approved, the daily pill would compete against a Bristol Myers Squibb drug projected to become a blockbuster seller.
Alan Murray on improving access for medical transportation.
In-home provider MedArrive can now connect members of its payer customers, particularly Medicaid plans, to Heartbeat Health for virtual cardiovascular services, the companies announced Tuesday.
A recent Elevance Health study found that long Covid patients are 2.35 times more likely to experience cardiac arrhythmia and 3.64 times more likely to experience pulmonary embolism. The study also discovered higher mortality rates among long Covid patients.
CardieX, a cardiovascular technology company based in both Australia and Illinois, recently acquired Blumio, a San Mateo, California-based startup focused on cardiovascular sensors. The deal will advance both companies’ vision to accurately and easily measure blood pressure without relying on the use of a cuff.
A Cytokinetics drug in development for treating a rare heart disorder has promising Phase 2 data suggesting it could compete against a Bristol Myers Squibb drug currently under FDA review. Cytokinetics plans to advance its small molecule to Phase 3 testing by the end of this year.
The Blue Cross Blue Shield Association recently announced its new national health equity strategy that will focus on maternal health, diabetes, cardiovascular care and mental health. The association's first goal is to cut racial disparities in maternal health by 50% in the next five years.